Fusion Polypeptide Antagonist for IL4 and IL13
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a need for effective therapy targeting interleukin 4 (IL4) and interleukin 13 (IL13) to treat autoimmune diseases, as current therapies are inadequate in inhibiting these cytokines effectively.
Innovation Solution
A fusion polypeptide comprising IL13Rα2 and IL4Rα sequences, potentially modified with non-natural amino acids or modifications such as pegylation, is designed to act as an antagonist of IL4 and IL13, with a regulatory component like the Fc domain to enhance pharmacokinetic properties like half-life and stability.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current therapies are used to target IL4 and IL13, then treatment is provided, but the inhibition effectiveness is inadequate
Solution Approach 1:
The patent combines IL13Rα2 and IL4Rα into a single fusion polypeptide molecule, creating a dual-specificity antagonist that can simultaneously bind and inhibit both IL13 and IL4. This merging approach resolves the contradiction by providing comprehensive cytokine inhibition through one therapeutic agent, thereby improving both reliability and productivity of the treatment.
Solution Approach 2:
The fusion polypeptide is designed with multi-functional capability to antagonize both IL4 and IL13 pathways. By incorporating receptor domains from both IL13Rα2 and IL4Rα, the single molecule performs multiple therapeutic functions that were previously requiring separate agents, thus enhancing overall therapeutic efficacy while maintaining reliable inhibition.
2Duration of action of stationary object
If fusion polypeptide with regulatory component is used, then pharmacokinetic properties like half-life are improved, but device complexity increases
Solution Approach 1:
The regulatory component acts as an intermediary element that mediates between the fusion polypeptide and the body's immune system. By adding this mediator component (such as Fc domain), the half-life is extended through enhanced stability and reduced clearance, while the added complexity is justified by the significant improvement in pharmacokinetic properties.
3Manufacturing precision
If fusion polypeptide is designed with high specificity, then therapeutic precision is improved, but manufacturing complexity increases
Solution Approach 1:
The fusion polypeptide is segmented into distinct functional domains (IL13Rα2 domain, IL4Rα domain, and regulatory component domain) connected by flexible linkers. This segmentation allows for modular construction and simplifies the manufacturing process while maintaining high therapeutic precision, as each domain can be independently optimized and assembled through standard recombinant DNA techniques.
Data Source
AI summary
Provided is a fusion polypeptide as an antagonist for IL4 and IL13. Also provided is a pharmaceutical composition comprising the fusion polypeptide and a pharmaceutically acceptable excipient.